

## Supplementary methods

Supplementary methods .....	1
Alcohol consumption.....	2
BMI .....	2
Low density lipoprotein cholesterol .....	2
Smoking .....	3
Systolic blood pressure.....	3
Atrial Fibrillation .....	4
Coronary heart disease.....	4
Diabetes.....	4
Stroke .....	5
Supplementary figures .....	6
sFigure 1: Study flow chart.....	6
Supplementary tables.....	7
sTable 1: International Standard Classification for Education (ISCED) definitions .....	7
sTable 2: Studies providing causal evidence for cardiovascular risk factors included.....	7
sTable 3: ICD codes for coronary artery disease, stroke and type 2 diabetes.....	7
sTable 4: ICD codes for cardiovascular exclusions.....	8
sTable 5: Number of single nucleotide polymorphisms (SNPs) and variance explained ( $R^2$ ) by polygenic scores for cardiovascular risk factors and outcomes .....	8
sTable 6: Association between educational attainment and observed phenotypic trait adjusted for age and sex.....	9
sTable 7: Association between polygenic scores for susceptibility to continuous cardiovascular risk factors and phenotypic measure of each risk factor, stratified by educational attainment demonstrating effect modification .....	10
sTable 8: Association between polygenic scores for susceptibility to cardiovascular risk factors and diseases and phenotypic measure of each risk factor or disease, stratified by educational attainment demonstrating effect modification .....	11
sTable 9: Association between polygenic scores for susceptibility to continuous cardiovascular risk factors and phenotypic measure of each risk factor, stratified by educational attainment demonstrating effect modification using polygenic scores at a range of P value thresholds .....	12
sTable 10: Association between polygenic scores for susceptibility to cardiovascular risk factors and diseases and phenotypic measure of each risk factor or disease, stratified by educational attainment demonstrating effect modification using polygenic scores at a range of P value thresholds .....	14

## Alcohol consumption

Alcohol consumption was defined as the number of drinks consumed per week. At baseline assessment centres, participants were asked to describe current drinking status (current, former or never) and estimate their current alcohol intake. Of those reporting a current frequency of at least once or twice a week, they were asked to estimate their current average weekly intake of different alcohol beverages. These were summed together to estimate an average number of drinks per week. Individuals reporting a current intake of “one to three times a month” or less frequently, were assumed to have a weekly intake of 0. This variable has been described in detail previously (1).

Summary statistics from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) GWAS of drinks per week were used for the polygenic score (2). This GWAS included predominantly European participants, excluding participants from UK Biobank to avoid sample overlap.

## BMI

Baseline measures of height and weight were used to calculate BMI ( $\text{kg}/\text{m}^2$ ).

Summary statistics for use in the polygenic score for BMI came from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium genome-wide association study (GWAS) analysis of 339 224 individuals with European ancestry (3). This is the most recent GWAS of BMI not including UK Biobank, where overlapping samples for the discovery and analysis dataset can lead to inflated effect estimates.

## Low density lipoprotein cholesterol

Non-fasting measures of low-density lipoprotein cholesterol were measured using enzymatic assays (Backman Coulter AU5800). UK Biobank corrected serum data for laboratory dilution effects and were excluded if they did not pass UK Biobank quality control (4).

Summary statistics for use in the polygenic score came from the Global Lipids Genetics consortium, which included 188 577 males and females of predominantly European ancestry (5).

## Smoking

A measure of lifetime smoking was constructed in the UK Biobank from self-reported age at initiation, age at cessation and cigarettes per day. From this information, smoking duration and time since cessation were calculated. The lifetime smoking measure further includes a simulated constant (half-life) which captures the exponentially decreasing effect of cigarettes on health over time. Aspects of smoking behaviour were combined into one score ranging from 0 (for non-smokers) to 4.00 (mean = 0.33, standard deviation = 0.67). Full details of score construction can be found elsewhere (6). The main advantage of using this measure of smoking is that it is a continuous measure, improving statistical power, and it considers all aspects of smoking which may affect health, e.g. duration of smoking and smoking heaviness.

We carried out a split sample GWAS of lifetime smoking in UK Biobank to identify genetic variants associated with lifetime smoking to use in a polygenic score. We included 318 147 participants with White British ancestry, who were randomly assigned to one of two samples. In each half of the eligible participants, the GWAS was conducted, which was used to derive the polygenic score in the opposing sample so as to avoid sample overlap which can inflate genetic estimates. This split sample GWAS of lifetime smoking has previously been used in a polygenic score and described in detail (7). The estimates from each sample were meta-analysed to create a single estimate of interaction for smoking.

## Systolic blood pressure

The mean from two resting automated measures of systolic blood pressure, measured using an Omron HEM-7105IT digital blood pressure monitor at baseline assessment centres was used for phenotypic measurements.

We carried out a split sample GWAS of systolic blood pressure in UK Biobank to identify genetic variants for use in the polygenic score. For individuals who reported taking antihypertensive medication to UK Biobank study nurses, we added 10mm Hg to the phenotypic measurement of systolic blood pressure (8). This GWAS was conducted as described previously for smoking and has been described in detail previously (7). The estimates from each sample were meta-analysed to create a single estimate of interaction for systolic blood pressure.

## Atrial Fibrillation

Atrial fibrillation events were ascertained through linkage to mortality data and hospital episode statistics (HES) and Scottish morbidity records (SMR), referred to jointly as hospital inpatient records. Cases were defined according to ICD-9 and ICD-10 codes (see sTable 2 for ICD codes used in case definition). Date of diagnoses are provided by HES data, which was linked with the date of assessment centre provided by UK Biobank to identify incident and prevalent cases.

Summary statistics for use in the polygenic score were from a 2012 GWAS of 59 133 individuals (6 707 cases) of European ancestry (9).

## Coronary heart disease

Coronary heart disease (CHD) events were ascertained through linkage to mortality data and hospital inpatient records, with cases defined according to ICD-9 and ICD-10 codes (see sTable 2 for ICD codes used in case definition) (10). Date of diagnoses are provided by hospital inpatient records, which was linked with the date of assessment centre provided by UK Biobank to identify incident and prevalent cases.

Summary statistics from the most recent GWAS for CHD not including UK Biobank were used for deriving the polygenic score (11). A total of 184 305 individuals (60 801 cases) were included in this GWAS of predominantly European descent.

## Diabetes

Type 2 diabetes was ascertained by linkage to HES data (sTable 2), with date of diagnosis defined by hospital inpatient records. Additionally, individuals were defined as diabetes if they had reported to UK Biobank study nurses that they had ever had diabetes diagnosed by a doctor (variable 2443). This variable does not distinguish between type 1 and type 2 diabetes, however individuals with a hospital inpatient record for type 1 diabetes were excluded from analyses and in this adult population new diagnoses are more likely to be type 2 diabetes. Individuals were defined as a prevalent case if they reported a diagnosis at baseline assessment centres (variable n\_2443\_0\_0). Incident cases were defined as those who reported a diagnosis at follow up clinics (variable n\_2443\_1\_0 and variable

n\_2443\_2\_0), with no previous diagnosis reported (although only a subset of individuals have follow up measures).

Summary statistics of 158 808 European individuals (26 276 Cases) from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium GWAS of type 2 diabetes were used for the polygenic score (12).


### Stroke

Stroke events (all subtypes) were ascertained through linkage to mortality data and HES data, with cases defined according to ICD-9 and ICD-10 codes (supplementary table 2) (10). Date of diagnoses are provided by hospital inpatient records, which was linked with the date of assessment centre provided by UK Biobank to identify incident and prevalent cases.

For the polygenic score, summary statistics for all subtypes of stroke were obtained from the MEGASTROKE consortium, consisting of 521 612 males and females (67 162 cases) of predominantly European ancestry (13).

## Supplementary figures

sFigure 1: Study flow chart



## Supplementary tables

sTable 1: International Standard Classification for Education (ISCED) definitions

Qualification (As reported in UK Biobank)	ISCED	Years of education
College or University degree	5	20
NVQ or HND or HNC or equivalent	5	19
Other prof. qual. eg: nursing, teaching	4	15
A levels/AS levels or equivalent	3	13
O levels/GCSEs or equivalent	2	10
CSEs or equivalent	2	10
None of the above	1	7
Prefer not to answer		Excluded

sTable 2: Studies providing causal evidence for cardiovascular risk factors included

Risk factor	Study	Study design
Alcohol (drinks per week)	Millwood <i>et al</i> , 2019 (14)	Mendelian randomization study
BMI	Carter <i>et al</i> , 2019 (7); Larsson <i>et al</i> , 2020 (15)	Mendelian randomization study; Mendelian randomization study
Low density lipoprotein cholesterol	Ference <i>et al</i> , 2018 (16) 2017;38(32):2459-72; Cheung <i>et al</i> , 2004 (17)	Mendelian randomization and clinical study; randomized controlled trial
Smoking (lifetime behaviour)	Larsson <i>et al</i> , 2020 (18)	Mendelian randomization study
Systolic blood pressure	Carter <i>et al</i> , 2019 (7); Ettehad <i>et al</i> , 2016 (19),	Mendelian randomization study; systematic review including randomized controlled trial
Type 2 diabetes	Ahmad <i>et al</i> , 2015 (20)	Mendelian randomization study

sTable 3: ICD codes for coronary artery disease, stroke and type 2 diabetes

Diagnosis	ICD9	ICD10
Atrial Fibrillation	42731	I48
Coronary heart disease	4100 - 4149	I20-I25
Stroke	4300 - 4389	I6, G45
Type 2 diabetes	4359	G45

sTable 4: ICD codes for cardiovascular exclusions

Cardiovascular event	ICD9	ICD10
Myocardial infarction	4100-4109, 4120-4129	I21, I22
Angina	4139	I20
Transient ischaemic attack	4359	G45
Peripheral arterial disease	4439	I73.9
Stroke	4349	I6, G45
Type 1 diabetes	2500- 25011, 25013, 2504-25041, 25043, 2505-25051, 25053, 2506-25061, 25063, 2507-25071, 25073, 2509-25091, 25093	E10
Chronic kidney disease	5383, 5384, 5385	N183, N184, N185
Familial hypercholesterolaemia	2720	I78.0

sTable 5: Number of single nucleotide polymorphisms (SNPs) and variance explained ( $R^2$ ) by polygenic scores for cardiovascular risk factors and outcomes

	$P \leq 5 \times 10^{-8}$		$P \leq 0.05$		$P \leq 0.5$	
	$N_{\text{SNPs}}$	$R^2$	$N_{\text{SNPs}}$	$R^2$	$N_{\text{SNPs}}$	$R^2$
Alcohol (drinks per week)	14	0.0840	72 962	0.0857	449 080	0.0857
Body mass index	127	0.0276	20 542	0.0646	139 582	0.0674
Low density lipoprotein cholesterol	398	0.0540	23 724	0.0144	13 337	0.0136
Systolic blood pressure (sample 1 GWAS)	126	0.1407	77 709	0.1579	373 402	0.1574
Systolic blood pressure (sample 2 GWAS)	112	0.1426	76 557	0.1633	372 715	0.1606
Smoking (sample 1 GWAS)	23	0.0097	67 741	0.0200	391 104	0.0206
Smoking (sample 2 GWAS)	21	0.0113	66 909	0.0222	390 557	0.0223
Atrial fibrillation	341	0.0061	60 738	0.0655	361 969	0.1064
Coronary heart disease	82	0.0654	49 098	0.0661	345 040	0.0656
Type 2 diabetes	18	0.0411	5 137	0.0366	134 673	0.0350
Stroke	11	0.0474	63 025	0.0480	373 240	0.0472



sTable 6: Association between per unit increase in educational attainment and observed phenotypic trait adjusted for age and sex

<b>Trait</b>	<b>Mean difference in SD of phenotypic trait (95% CI)</b>
Alcohol (drinks per week)	0.010 (0.009, 0.011)
BMI	-0.020 (-0.021, -0.020)
Low density lipoprotein cholesterol	$5.1 \times 10^{-4}$ ( $-2.0 \times 10^{-4}$ , $1.2 \times 10^{-3}$ )
Smoking (lifetime behaviour)	-0.028 (-0.028, -0.027)
Systolic blood pressure	-0.012 (-0.012, -0.011)
	<b>Risk difference of outcome (95% CI)</b>
Atrial fibrillation	$-5.1 \times 10^{-4}$ ( $-6.3 \times 10^{-4}$ , $-3.9 \times 10^{-4}$ )
Coronary artery disease	$-1.6 \times 10^{-3}$ ( $-1.7 \times 10^{-3}$ , $-1.5 \times 10^{-3}$ )
Diabetes (type 2)	$-1.7 \times 10^{-3}$ ( $-1.8 \times 10^{-3}$ , $-1.6 \times 10^{-3}$ )
Stroke	$-5.7 \times 10^{-4}$ ( $-6.6 \times 10^{-4}$ , $-4.7 \times 10^{-4}$ )

Table 7: Association between polygenic scores for susceptibility to continuous cardiovascular risk factors and phenotypic measure of each risk factor, stratified by educational attainment demonstrating effect modification

Trait	Years of education	N	Additive scale		Multiplicative scale	
			Mean difference in SD of phenotypic trait (95% CI)	P value for effect modification	Mean difference in SD of log phenotypic trait (95% CI)	P value for effect modification
Alcohol	All	318 300	0.046 (0.042, 0.049)	0.384	0.049 (0.046, 0.053)	0.976
	Education 7	51 509	0.037 (0.029, 0.046)		0.040 (0.031, 0.049)	
	Education 10	54 567	0.05 (0.042, 0.058)		0.058 (0.049, 0.066)	
	Education 13	17 267	0.045 (0.03, 0.059)		0.052 (0.037, 0.066)	
	Education 15	38 974	0.051 (0.041, 0.06)		0.056 (0.046, 0.065)	
	Education 19	51 095	0.05 (0.041, 0.059)		0.047 (0.039, 0.056)	
	Education 20	104 888	0.045 (0.039, 0.05)		0.048 (0.043, 0.053)	
	Effect modification coefficient		2.93x10 <sup>-4</sup> (-3.66x10 <sup>-4</sup> , 9.51x10 <sup>-4</sup> )			
BMI	All	319 201	0.128 (0.124, 0.131)	0.036	0.128 (0.125, 0.131)	0.330
	Education 7	51 773	0.129 (0.12, 0.138)		0.126 (0.118, 0.135)	
	Education 10	54 739	0.133 (0.125, 0.142)		0.132 (0.124, 0.14)	
	Education 13	17 319	0.131 (0.116, 0.146)		0.131 (0.116, 0.146)	
	Education 15	39 041	0.129 (0.119, 0.138)		0.129 (0.119, 0.138)	
	Education 19	51 309	0.136 (0.128, 0.145)		0.134 (0.126, 0.143)	
	Education 20	105 020	0.117 (0.111, 0.122)		0.121 (0.115, 0.126)	
	Effect modification coefficient		-7.20x10 <sup>-4</sup> (-1.40x10 <sup>-3</sup> , -4.90x10 <sup>-5</sup> )			
Low density lipoprotein cholesterol	All	304 700	0.211 (0.208, 0.215)	1.12x10 <sup>-4</sup>	0.209 (0.206, 0.212)	1.63x10 <sup>-6</sup>
	Education 7	49 435	0.186 (0.177, 0.195)		0.18 (0.171, 0.189)	
	Education 10	52 311	0.219 (0.211, 0.227)		0.216 (0.208, 0.224)	
	Education 13	16 521	0.224 (0.209, 0.238)		0.221 (0.207, 0.236)	
	Education 15	37 257	0.209 (0.199, 0.219)		0.206 (0.196, 0.215)	
	Education 19	48 942	0.206 (0.197, 0.214)		0.204 (0.196, 0.213)	
	Education 20	100 234	0.222 (0.216, 0.227)		0.221 (0.215, 0.227)	
	Effect modification coefficient		1.34x10 <sup>-3</sup> (6.62x10 <sup>-4</sup> , 2.02x10 <sup>-3</sup> )			
Smoking (lifetime behaviour)	All	301 684	0.039 (0.035, 0.042)	0.001	0.039 (0.035, 0.042)	0.008
	Education 7	48 470	0.053 (0.042, 0.064)		0.05 (0.039, 0.061)	
	Education 10	52 292	0.035 (0.026, 0.044)		0.036 (0.027, 0.044)	
	Education 13	16 261	0.026 (0.012, 0.041)		0.026 (0.011, 0.041)	
	Education 15	37 149	0.046 (0.036, 0.055)		0.046 (0.036, 0.055)	
	Education 19	48 639	0.042 (0.032, 0.051)		0.042 (0.033, 0.052)	
	Education 20	98 873	0.029 (0.024, 0.034)		0.03 (0.025, 0.035)	
	Effect modification coefficient		-1.08x10 <sup>-3</sup> (-0.02, -3.70x10 <sup>-4</sup> )			
Systolic blood pressure	All	292 277	0.089 (0.086, 0.092)	0.104	0.070 (0.066, 0.074)	0.076
	Education 7	46 726	0.080 (0.071, 0.089)		0.058 (0.050, 0.067)	
	Education 10	50 789	0.087 (0.079, 0.095)		0.069 (0.06, 0.079)	
	Education 13	15 772	0.094 (0.080, 0.108)		0.081 (0.064, 0.097)	
	Education 15	36 033	0.099 (0.089, 0.108)		0.078 (0.067, 0.088)	
	Education 19	47 177	0.088 (0.08, 0.097)		0.068 (0.058, 0.077)	
	Education 20	95 780	0.090 (0.084, 0.096)		0.073 (0.066, 0.08)	
	Effect modification coefficient		6.97x10 <sup>-4</sup> (1.03x10 <sup>-5</sup> , 1.38x10 <sup>-3</sup> )			

Table 8: Association between polygenic scores for susceptibility to cardiovascular risk factors and diseases and phenotypic measure of each risk factor or disease, stratified by educational attainment demonstrating effect modification

Trait	Years of education	N	N cases	Additive scale		Multiplicative scale	
				Risk difference (95% CI)	P value for effect modification	OR (95% CI)	P value for effect modification
Atrial fibrillation	All	316 912	9 560	0.0137 (0.0131, 0.0143)	9.03x10 <sup>-08</sup>	1.59 (1.55, 1.62)	0.008
	Education 7	51 246	2 438	0.0188 (0.017, 0.0206)		1.51 (1.45, 1.57)	
	Education 10	54 460	1 466	0.0123 (0.0109, 0.0136)		1.59 (1.51, 1.67)	
	Education 13	17 213	446	0.0126 (0.0102, 0.015)		1.66 (1.51, 1.82)	
	Education 15	38 694	1 232	0.0147 (0.0129, 0.0164)		1.60 (1.51, 1.69)	
	Education 19	50 942	1 396	0.0125 (0.0111, 0.0139)		1.58 (1.5, 1.67)	
	Education 20	104 357	2 582	0.0123 (0.0113, 0.0132)		1.65 (1.59, 1.71)	
	Effect modification coefficient			-3.20x10 <sup>-4</sup> (-4.30x10 <sup>-4</sup> , -2.00x10 <sup>-4</sup> )		1.00 (1.00, 1.01)	
Coronary heart disease	All	317 055	14 481	0.0085 (0.0077, 0.0092)	0.103	1.22 (1.2, 1.24)	0.001
	Education 7	51 061	3 989	0.0115 (0.0091, 0.0138)		1.18 (1.14, 1.21)	
	Education 10	54 483	2 292	0.0079 (0.0062, 0.0095)		1.22 (1.17, 1.28)	
	Education 13	17 220	581	0.0053 (0.0027, 0.008)		1.18 (1.09, 1.28)	
	Education 15	38 740	1 733	0.0073 (0.0053, 0.0094)		1.19 (1.14, 1.25)	
	Education 19	50 912	2 477	0.0087 (0.0069, 0.0106)		1.22 (1.17, 1.27)	
	Education 20	104 639	3 409	0.0082 (0.0071, 0.0092)		1.30 (1.26, 1.35)	
	Effect modification coefficient			-1.20x10 <sup>-4</sup> (-2.60x10 <sup>-4</sup> , 2.39x10 <sup>-5</sup> )		1.00 (1.00, 1.01)	
Diabetes (Type 2)	All	316 406	11 079	0.0081 (0.0074, 0.0087)	3.23x10 <sup>-10</sup>	1.27 (1.24, 1.29)	0.537
	Education 7	50 904	3 175	0.0131 (0.011, 0.0152)		1.25 (1.2, 1.29)	
	Education 10	54 261	1 809	0.0088 (0.0073, 0.0103)		1.31 (1.25, 1.37)	
	Education 13	17 190	512	0.0062 (0.0037, 0.0087)		1.23 (1.13, 1.35)	
	Education 15	38 683	1 336	0.0074 (0.0056, 0.0092)		1.24 (1.18, 1.31)	
	Education 19	50 814	1 914	0.0087 (0.007, 0.0103)		1.26 (1.21, 1.32)	
	Education 20	104 554	2 333	0.0057 (0.0048, 0.0066)		1.29 (1.24, 1.35)	
	Effect modification coefficient			-4.00x10 <sup>-4</sup> (-5.30x10 <sup>-4</sup> , -2.80x10 <sup>-4</sup> )		1.00 (1.00, 1.00)	
Stroke	NONE	320 120	5 929	0.0009 (0.0005, 0.0014)	0.036	1.05 (1.03, 1.08)	0.292
	Education 7	52 012	1 620	0.002 (0.0005, 0.0035)		1.07 (1.02, 1.12)	
	Education 10	54 899	948	0.0007 (-0.0004, 0.0018)		1.04 (0.98, 1.11)	
	Education 13	17 355	311	0.0026 (0.0006, 0.0045)		1.16 (1.03, 1.29)	
	Education 15	39 144	731	0.0009 (-0.0005, 0.0022)		1.05 (0.97, 1.13)	
	Education 19	51 418	874	0.0016 (0.0005, 0.0027)		1.10 (1.03, 1.17)	
	Education 20	105 292	1 445	-4.83x10 <sup>-5</sup> (-0.0007, 0.0007)		1.00 (0.95, 1.05)	
	Effect modification coefficient			-9.80x10 <sup>-5</sup> (-1.90x10 <sup>-4</sup> , -6.40x10 <sup>-6</sup> )		1.00 (0.99, 1.00)	

sTable 9: Association between polygenic scores for susceptibility to continuous cardiovascular risk factors and phenotypic measure of each risk factor, stratified by educational attainment demonstrating effect modification using polygenic scores at a range of P value thresholds

Exposure	Educational attainment	N	P≤0.05				P≤0.5			
			Additive scale		Multiplicative scale		Additive scale		Multiplicative scale	
			Mean difference in SD of phenotypic trait (95%CI)	P value for effect modification	Mean difference in SD of log phenotypic trait (95%CI)	P value for effect modification	Mean difference in SD of phenotypic trait (95%CI)	P value for effect modification	Mean difference in SD of log phenotypic trait (95%CI)	P value for effect modification
Alcohol	All years	318,300	0.063 (0.06, 0.066)	0.694	0.064 (0.061, 0.068)	0.108	0.064 (0.061, 0.068)	0.669	0.065 (0.062, 0.069)	0.04
	Education 7	51,509	0.056 (0.048, 0.065)		0.062 (0.053, 0.071)		0.058 (0.05, 0.067)		0.065 (0.056, 0.074)	
	Education 10	54,567	0.069 (0.061, 0.077)		0.07 (0.062, 0.079)		0.069 (0.061, 0.077)		0.071 (0.062, 0.079)	
	Education 13	17,267	0.075 (0.06, 0.091)		0.075 (0.06, 0.09)		0.072 (0.057, 0.088)		0.075 (0.06, 0.09)	
	Education 15	38,974	0.064 (0.054, 0.073)		0.065 (0.055, 0.075)		0.069 (0.06, 0.079)		0.069 (0.059, 0.079)	
	Education 19	51,095	0.056 (0.047, 0.065)		0.058 (0.049, 0.067)		0.061 (0.052, 0.07)		0.062 (0.053, 0.071)	
	Education 20	104,888	0.063 (0.057, 0.069)		0.06 (0.055, 0.066)		0.062 (0.056, 0.068)		0.059 (0.053, 0.065)	
Effect modification coefficient			-1.31x10 <sup>-4</sup> (-7.85x10 <sup>-4</sup> , 5.23x10 <sup>-4</sup> )		-5.39x10 <sup>-4</sup> (-1.19x10 <sup>-3</sup> , 1.18x10 <sup>-4</sup> )		-1.43x10 <sup>-4</sup> (-7.95x10 <sup>-4</sup> , 5.10x10 <sup>-4</sup> )		-6.68x10 <sup>-4</sup> (-1.32x10 <sup>-3</sup> , -1.25x10 <sup>-5</sup> )	
Body mass index	All years	319,201	0.229 (0.225, 0.232)	0.005	-0.018 (-0.021, -0.014)	0.453	0.235 (0.231, 0.238)	0.215	0.237 (0.233, 0.24)	0.396
	Education 7	51,773	0.225 (0.216, 0.233)		0.220 (0.212, 0.229)		0.228 (0.219, 0.237)		0.224 (0.215, 0.232)	
	Education 10	54,739	0.239 (0.231, 0.248)		0.239 (0.231, 0.247)		0.24 (0.232, 0.249)		0.24 (0.232, 0.249)	
	Education 13	17,319	0.235 (0.22, 0.25)		0.238 (0.223, 0.253)		0.245 (0.23, 0.26)		0.250 (0.235, 0.264)	
	Education 15	39,041	0.234 (0.224, 0.243)		0.235 (0.226, 0.245)		0.235 (0.225, 0.244)		0.236 (0.227, 0.246)	
	Education 19	51,309	0.235 (0.226, 0.243)		0.233 (0.225, 0.241)		0.238 (0.23, 0.247)		0.237 (0.228, 0.245)	
	Education 20	105,020	0.210 (0.204, 0.215)		0.217 (0.212, 0.223)		0.221 (0.216, 0.227)		0.229 (0.224, 0.235)	
Effect modification coefficient			-9.56x10 <sup>-4</sup> (-1.62x10 <sup>-3</sup> , -2.96x10 <sup>-4</sup> )		-2.52x10 <sup>-4</sup> (-9.10x10 <sup>-4</sup> , 4.06x10 <sup>-4</sup> )		-4.17x10 <sup>-4</sup> (-1.07x10 <sup>-3</sup> , 2.42x10 <sup>-4</sup> )		2.85x10 <sup>-4</sup> (-3.72x10 <sup>-4</sup> , 9.42x10 <sup>-4</sup> )	
Low density lipoprotein cholesterol	All years	304,700	0.071 (0.068, 0.075)	0.148	0.056 (0.052, 0.059)	0.056	0.065 (0.062, 0.069)	0.072	0.063 (0.06, 0.067)	0.033
	Education 7	49,435	0.059 (0.05, 0.068)		0.056 (0.047, 0.065)		0.052 (0.043, 0.062)		0.050 (0.04, 0.059)	
	Education 10	52,311	0.08 (0.071, 0.088)		0.077 (0.068, 0.085)		0.073 (0.065, 0.082)		0.071 (0.062, 0.079)	
	Education 13	16,521	0.069 (0.054, 0.084)		0.066 (0.051, 0.081)		0.069 (0.055, 0.084)		0.065 (0.05, 0.08)	
	Education 15	37,257	0.069 (0.059, 0.08)		0.067 (0.057, 0.077)		0.057 (0.047, 0.067)		0.054 (0.044, 0.064)	
	Education 19	48,942	0.069 (0.06, 0.078)		0.068 (0.059, 0.077)		0.066 (0.058, 0.075)		0.064 (0.056, 0.073)	
	Education 20	100,234	0.075 (0.069, 0.081)		0.074 (0.068, 0.08)		0.069 (0.063, 0.075)		0.068 (0.062, 0.074)	
Effect modification coefficient			5.12x10 <sup>-4</sup> (-1.82x10 <sup>-4</sup> , 1.21x10 <sup>-3</sup> )		6.79x10 <sup>-4</sup> (-1.61x10 <sup>-5</sup> , 1.37x10 <sup>-3</sup> )		6.38x10 <sup>-4</sup> (-5.80x10 <sup>-5</sup> , 1.33x10 <sup>-3</sup> )		7.59x10 <sup>-4</sup> (6.21x10 <sup>-5</sup> , 1.46x10 <sup>-3</sup> )	

Smoking (lifetime behaviour)	All years	301,684	0.133 (0.128, 0.137)	$2.16 \times 10^{-52}$	0.135 (0.13, 0.14)	$6.10 \times 10^{-40}$	0.150 (0.145, 0.155)	$8.85 \times 10^{-50}$	0.152 (0.147, 0.157)	$9.83 \times 10^{-38}$
	Education 7	48,470	0.184 (0.169, 0.198)		0.178 (0.165, 0.192)		0.197 (0.181, 0.213)		0.192 (0.177, 0.208)	
	Education 10	52,292	0.136 (0.124, 0.147)		0.137 (0.125, 0.149)		0.155 (0.142, 0.168)		0.157 (0.144, 0.169)	
	Education 13	16,261	0.114 (0.095, 0.133)		0.119 (0.1, 0.139)		0.128 (0.107, 0.149)		0.132 (0.111, 0.154)	
	Education 15	37,149	0.120 (0.108, 0.132)		0.122 (0.11, 0.135)		0.136 (0.122, 0.149)		0.139 (0.125, 0.152)	
	Education 19	48,639	0.141 (0.128, 0.153)		0.142 (0.129, 0.154)		0.165 (0.151, 0.178)		0.166 (0.152, 0.179)	
	Education 20	98,873	0.090 (0.084, 0.097)		0.097 (0.09, 0.103)		0.101 (0.094, 0.108)		0.109 (0.101, 0.116)	
	Effect modification coefficient		$-6.21 \times 10^{-3}$ ( $-7.01 \times 10^{-3}$ , $-5.41 \times 10^{-3}$ )		$-5.39 \times 10^{-3}$ ( $-6.19 \times 10^{-3}$ , $-4.59 \times 10^{-3}$ )		$-6.38 \times 10^{-3}$ ( $-7.22 \times 10^{-3}$ , $5.54 \times 10^{-3}$ )		$-5.52 \times 10^{-3}$ ( $-6.37 \times 10^{-3}$ , $-4.68 \times 10^{-3}$ )	
Systolic blood pressure	All years	292,277	0.193 (0.189, 0.197)	0.160	0.155 (0.150, 0.160)	0.127	0.204 (0.2, 0.209)	0.124	0.163 (0.158, 0.168)	0.191
	Education 7	46,726	0.181 (0.171, 0.192)		0.139 (0.129, 0.15)		0.189 (0.177, 0.2)		0.143 (0.131, 0.154)	
	Education 10	50,789	0.198 (0.188, 0.207)		0.165 (0.154, 0.176)		0.21 (0.2, 0.221)		0.177 (0.165, 0.189)	
	Education 13	15,772	0.205 (0.188, 0.222)		0.167 (0.147, 0.187)		0.225 (0.207, 0.243)		0.183 (0.161, 0.205)	
	Education 15	36,033	0.191 (0.179, 0.202)		0.145 (0.133, 0.158)		0.2 (0.188, 0.212)		0.153 (0.139, 0.167)	
	Education 19	47,177	0.182 (0.173, 0.192)		0.144 (0.133, 0.155)		0.195 (0.184, 0.205)		0.151 (0.139, 0.163)	
	Education 20	95,780	0.197 (0.19, 0.204)		0.163 (0.155, 0.172)		0.208 (0.2, 0.215)		0.169 (0.16, 0.178)	
	Effect modification coefficient		$5.62 \times 10^{-4}$ ( $-2.22 \times 10^{-4}$ , $1.35 \times 10^{-3}$ )		$6.90 \times 10^{-4}$ ( $-1.97 \times 10^{-4}$ , $1.58 \times 10^{-3}$ )		$6.73 \times 10^{-4}$ ( $-1.84 \times 10^{-4}$ , $1.53 \times 10^{-3}$ )		$6.45 \times 10^{-4}$ ( $-3.24 \times 10^{-4}$ , $1.61 \times 10^{-3}$ )	

sTable 10: Association between polygenic scores for susceptibility to cardiovascular risk factors and diseases and phenotypic measure of each risk factor or disease, stratified by educational attainment demonstrating effect modification using polygenic scores at a range of P value thresholds

Exposure	Educational attainment	N	P≤0.05				P≤0.5			
			Additive interaction		Multiplicative interaction		Additive interaction		Multiplicative interaction	
			Risk difference of phenotypic trait (95%CI)	P value for effect modification	Odds ratio of phenotypic trait (95%CI)	P value for effect modification	Risk difference of phenotypic trait (95%CI)	P value for effect modification	Odds ratio of phenotypic trait (95%CI)	P value for effect modification
Atrial fibrillation	All years	316,912	0.0454 (0.0448, 0.046)		4.67 (4.56, 4.79)		0.0586 (0.058, 0.0592)		5.88 (5.73, 6.03)	
	Education 7	51,246	0.0658 (0.0641, 0.0675)	4.52x10 <sup>-112</sup>	4.44 (4.22, 4.67)	0.004	0.0827 (0.081, 0.0844)	4.97x10 <sup>-167</sup>	5.51 (5.23, 5.8)	2.87x10 <sup>-4</sup>
	Education 10	54,460	0.0401 (0.0387, 0.0414)		4.5 (4.23, 4.79)		0.0519 (0.0506, 0.0533)		5.58 (5.23, 5.95)	
	Education 13	17,213	0.0392 (0.0369, 0.0415)		4.88 (4.34, 5.48)		0.052 (0.0497, 0.0544)		6.49 (5.74, 7.35)	
	Education 15	38,694	0.0474 (0.0457, 0.0491)		4.71 (4.4, 5.05)		0.0607 (0.059, 0.0624)		5.77 (5.37, 6.2)	
	Education 19	50,942	0.0427 (0.0413, 0.0441)		4.92 (4.61, 5.26)		0.0557 (0.0543, 0.0571)		6.4 (5.97, 6.86)	
	Education 20	104,357	0.0391 (0.0382, 0.04)		4.83 (4.6, 5.06)		0.0507 (0.0498, 0.0517)		6.15 (5.85, 6.46)	
	Effect modification coefficient		-1.31x10 <sup>-3</sup> (-1.42x10 <sup>-3</sup> , -1.19x10 <sup>-3</sup> )		1.01 (1.00, 1.01)		-1.57x10 <sup>-3</sup> (-1.69x10 <sup>-3</sup> , -1.46x10 <sup>-3</sup> )		1.01 (1.00, 1.01)	
Coronary heart disease	All years	317,055	0.0088 (0.008, 0.0095)				1.23 (1.21, 1.25)			
	Education 7	51,061	0.013 (0.0107, 0.0153)	8.79x10 <sup>-06</sup>	1.2 (1.16, 1.24)	0.372	0.0132 (0.0109, 0.0155)	3.03x10 <sup>-4</sup>	1.21 (1.17, 1.25)	0.140
	Education 10	54,483	0.0085 (0.0068, 0.0102)		1.24 (1.19, 1.3)		0.0067 (0.005, 0.0084)		1.19 (1.14, 1.24)	
	Education 13	17,220	0.0078 (0.0051, 0.0104)		1.28 (1.18, 1.4)		0.0063 (0.0036, 0.009)		1.23 (1.13, 1.34)	
	Education 15	38,740	0.0083 (0.0062, 0.0103)		1.22 (1.16, 1.28)		0.0076 (0.0056, 0.0097)		1.2 (1.14, 1.26)	
	Education 19	50,912	0.0085 (0.0066, 0.0103)		1.21 (1.16, 1.26)		0.0078 (0.0059, 0.0096)		1.19 (1.14, 1.24)	
	Education 20	104,639	0.0069 (0.0059, 0.008)		1.26 (1.21, 1.3)		0.0073 (0.0063, 0.0084)		1.27 (1.23, 1.31)	
	Effect modification coefficient		-3.22x10 <sup>-4</sup> (-4.64x10 <sup>-4</sup> , 1.80x10 <sup>-4</sup> )		1.00 (1.00, 1.00)		-2.61x10 <sup>-4</sup> (-4.03x10 <sup>-4</sup> , 1.19x10 <sup>-4</sup> )		1.00 (1.00, 1.01)	
Diabetes (Type 2)	All years	316,406	0.0042 (0.0036, 0.0049)				1.14 (1.11, 1.16)			

	Education 7	50,904	0.0061 (0.004, 0.0082)	0.011	1.11 (1.07, 1.15)	0.273	0.0017 (-0.0004, 0.0037)	0.317	1.03 (0.99, 1.07)	0.705
	Education 10	54,261	0.0046 (0.0031, 0.0061)		1.15 (1.1, 1.21)		0.0024 (0.0009, 0.0039)		1.08 (1.03, 1.13)	
	Education 13	17,190	0.0028 (0.0002, 0.0053)		1.11 (1.01, 1.21)		0.0021 (-0.0004, 0.0047)		1.07 (0.98, 1.17)	
	Education 15	38,683	0.004 (0.0021, 0.0058)		1.13 (1.07, 1.19)		0.0009 (-0.0009, 0.0027)		1.03 (0.97, 1.09)	
	Education 19	50,814	0.0059 (0.0042, 0.0075)		1.18 (1.13, 1.24)		0.0018 (0.0002, 0.0035)		1.05 (1.01, 1.1)	
	Education 20	104,554	0.0027 (0.0019, 0.0036)		1.14 (1.09, 1.18)		0.0011 (0.0002, 0.002)		1.05 (1.01, 1.1)	
	Effect modification coefficient		-1.64x10 <sup>-4</sup> (-2.90x10 <sup>-4</sup> , -3.81x10 <sup>-5</sup> )		1.00 (1.00, 1.01)		-6.41x10 <sup>-5</sup> (-1.90x10 <sup>-4</sup> , 6.15x10 <sup>-5</sup> )		1.00 (1.00, 1.00)	

Stroke	All years	320,120	0.0016 (0.0012, 0.0021)	0.015	1.1 (1.07, 1.13)	0.538	0.0003 (-0.0001, 0.0008)	0.378	1.02 (0.99, 1.05)	0.666
	Education 7	52,012	0.0033 (0.0018, 0.0048)		1.12 (1.06, 1.17)		0.0007 (-0.0008, 0.0022)		1.02 (0.97, 1.08)	
	Education 10	54,899	0.001 (-0.0001, 0.0021)		1.06 (0.99, 1.13)		0.0005 (-0.0006, 0.0016)		1.03 (0.97, 1.1)	
	Education 13	17,355	0.0005 (-0.0015, 0.0025)		1.03 (0.92, 1.16)		0.0002 (-0.0018, 0.0022)		1.01 (0.9, 1.14)	
	Education 15	39,144	0.0024 (0.0011, 0.0038)		1.15 (1.06, 1.24)		0.0004 (-0.0009, 0.0018)		1.02 (0.95, 1.1)	
	Education 19	51,418	0.0011 (0, 0.0023)		1.07 (1, 1.15)		-0.0006 (-0.0017, 0.0005)		0.97 (0.9, 1.03)	
	Education 20	105,292	0.0013 (0.0006, 0.002)		1.1 (1.04, 1.16)		0.0005 (-0.0002, 0.0012)		1.04 (0.99, 1.1)	
	Effect modification coefficient		-1.31x10 <sup>-4</sup> (-2.05x10 <sup>-4</sup> , -2.17x10 <sup>-5</sup> )		1.00 (0.99, 1.00)		-4.13x10 <sup>-5</sup> (-1.33x10 <sup>-4</sup> , 5.05x10 <sup>-5</sup> )		1.00 (0.99, 1.00)	

## References

1. Howe LJ, Lawson DJ, Davies NM, St Pourcain B, Lewis SJ, Davey Smith G, et al. Genetic evidence for assortative mating on alcohol consumption in the UK Biobank. *Nat Commun*. 2019;10(1):5039.
2. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet*. 2019;51(2):237-44.
3. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518(7538):197-206.
4. Biobank U. Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). [http://biobank.ctsu.ox.ac.uk/showcase/showcase/docs/biomarker\\_issues.pdf](http://biobank.ctsu.ox.ac.uk/showcase/showcase/docs/biomarker_issues.pdf); 2019.
5. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45(11):1274-83.
6. Wootton RE, Richmond RC, Stuijzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. *Psychol Med*. 2019:1-9.
7. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. *BMJ*. 2019;365:l1855.
8. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat Med*. 2005;24(19):2911-35.
9. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet*. 2012;44(6):670-5.
10. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization. *Obesity (Silver Spring)*. 2018;26(11):1796-806.
11. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet*. 2015;47(10):1121-30.
12. Scott RA, Scott LJ, Magi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*. 2017;66(11):2888-902.
13. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. 2018;50(4):524-37.
14. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet*. 2019;393(10183):1831-42.
15. Larsson SC, Back M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. *Eur Heart J*. 2020;41(2):221-6.
16. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,



epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2017;38(32):2459-72.

17. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *Br J Clin Pharmacol.* 2004;57(5):640-51.

18. Larsson SC, Mason AM, Back M, Klarin D, Damrauer SM, Million Veteran P, et al. Genetic predisposition to smoking in relation to 14 cardiovascular diseases. *Eur Heart J.* 2020.

19. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387(10022):957-67.

20. Ahmad OS, Morris JA, Mujammami M, Forgetta V, Leong A, Li R, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. *Nat Commun.* 2015;6:7060.